ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia September 6, 2018
ContraFect to Present at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance August 22, 2018
ContraFect to Participate in FDA Workshop on Development of Non-Traditional Therapies for Bacterial Infections August 14, 2018
ContraFect to Present New Data on CF-301 (exebacase) and Lysins Targeting Gram-Negative Pathogens at ASM Microbe 2018 May 30, 2018
